T. Cameron
About
T. Cameron is a scholar working on Oncology, Reproductive Medicine and Molecular Biology.
According to data from OpenAlex, T. Cameron has authored 22 papers receiving a total of 118 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Reproductive Medicine and 5 papers in Molecular Biology. Recurrent topics in T. Cameron's work include Ovarian cancer diagnosis and treatment (10 papers), PARP inhibition in cancer therapy (10 papers) and Intraperitoneal and Appendiceal Malignancies (3 papers). T. Cameron is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), PARP inhibition in cancer therapy (10 papers) and Intraperitoneal and Appendiceal Malignancies (3 papers). T. Cameron collaborates with scholars based in United States, Spain and Italy. T. Cameron's co-authors include Gary M. Clark, Marta Hamilton, L. McIntosh, Susan Ellard, Jonathan A. Ledermann, Gordon C. Jayson, Tien Le, P. Vasey, Wendy Walsh and K. Swenerton and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.
In The Last Decade
T. Cameron
21 papers receiving 116 citations
Peers
T. Cameron
Sara Bastian Switzerland
Tracie Saunders United States
Ana C.F. Bolhaqueiro Netherlands
Francesca Pettinella United States
Salma El-Sahhar United Kingdom
Alena Heimsoeth Germany
Kay Y. Chong China
Chenlu Wang China
Stephen J. Luen Australia
Yuwen Qi China
Citations per year, relative to T. Cameron T. Cameron (= 1×)
peers
Sara Bastian
Countries citing papers authored by T. Cameron
Since
Specialization
Citations
This map shows the geographic impact of T. Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Cameron more than expected).
Fields of papers citing papers by T. Cameron
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by T. Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Cameron. The network helps show where T. Cameron may publish in the future.
Co-authorship network of co-authors of T. Cameron
This figure shows the co-authorship network connecting the top 25 collaborators of T. Cameron. A scholar is included among the top collaborators of T. Cameron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Cameron. T. Cameron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Concin, Nicole, Manish R. Patel, Vicky Makker, et al.. (2022). 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. International Journal of Gynecological Cancer. 32. A185–A185.
2.
Liao, Mingxiang, Jie Zhou, Kenton Wride, et al.. (2022). Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. European Journal of Drug Metabolism and Pharmacokinetics. 47(5). 711–723.
3.
Oaknin, Ana, Floor Backes, Els Van Nieuwenhuysen, et al.. (2022). LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034). Gynecologic Oncology. 166. S24–S24.
4.
Hamilton, Erika, Manish R. Patel, Kenton Wride, et al.. (2020). 556P Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116). Annals of Oncology. 31. S480–S481.
5.
Concin, Nicole, Sandro Pignata, Philipp Harter, et al.. (2020). 885TiP LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO). Annals of Oncology. 31. S648–S648.
6.
Dean, Andrew, Amit M. Oza, Domenica Lorusso, et al.. (2020). 821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology. 31. S620–S621.
7.
Kristeleit, Rebecca, Ana Oaknin, Isabelle Ray‐Coquard, et al.. (2019). Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer. 29(9). 1396–1404.
8.
Coleman, Robert L., Amit M. Oza, Domenica Lorusso, et al.. (2019). Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline mutation on efficacy. Gynecologic Oncology. 154. 237–237.
9.
Oaknin, Ana, N. Colombo, Johanne I. Weberpals, et al.. (2019). PCN295 PATIENT-CENTERED OUTCOMES IN ARIEL3, A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH RECURRENT OVARIAN CARCINOMA. Value in Health. 22. S112–S112.
10.
Ledermann, Jonathan A., Amit M. Oza, Domenica Lorusso, et al.. (2019). The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma. Gynecologic Oncology. 154. 4–5.
11.
Coleman, Robert L., Amit M. Oza, Domenica Lorusso, et al.. (2018). Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). Clinical Cancer Research. 24(15_Supplement). PR06–PR06.
12.
O’Malley, David M., Robert L. Coleman, Amit M. Oza, et al.. (2018). Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma. Molecular Cancer Therapeutics. 17(1_Supplement). LB–A12.
13.
Ledermann, Jonathan A., Amit M. Oza, Domenica Lorusso, et al.. (2017). ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC). Annals of Oncology. 28. v625–v625.
14.
Diao, Kevin, Jordan A. Holmes, Yanli Hou, et al.. (2012). Comparative Patient-reported Quality of Life (QOL) During Radiation Therapy (RT) in Patients Receiving Definitive RT Versus Postprostatectomy RT for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 84(3). S373–S373.
15.
Badura, Michelle L., Chunyan He, T. Cameron, et al.. (2006). CXCR6 and CXCL16 are expressed by breast cancer cells and may play a dual role in tumor progression.. Breast Cancer Research and Treatment. 100.
16.
Clark, Gary M., et al.. (2006). Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC. Journal of Clinical Oncology. 24(18_suppl). 7166–7166.
17.
Dark, G., A H Calvert, Robert Grimshaw, et al.. (2005). Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 23(9). 1859–1866.
18.
Poole, C. J., M. Gore, P. Vasey, et al.. (2005). Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 23(16_suppl). 5017–5017.
19.
Kehrer, Diederik F.S., Annelies M. E. Bos, Jaap Verweij, et al.. (2002). Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity. Journal of Clinical Oncology. 20(5). 1222–1231.
20.
Gore, M., Gordon Rustin, Mark Slevin, et al.. (1997). Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. British Journal of Cancer. 75(5). 710–714.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sara Bastian Breakdown of academic impact, for papers by Tracie Saunders Breakdown of academic impact, for papers by Ana C.F. Bolhaqueiro Breakdown of academic impact, for papers by Francesca Pettinella Breakdown of academic impact, for papers by Salma El-Sahhar Breakdown of academic impact, for papers by Alena Heimsoeth Breakdown of academic impact, for papers by Kay Y. Chong Breakdown of academic impact, for papers by Chenlu Wang Breakdown of academic impact, for papers by Stephen J. Luen Breakdown of academic impact, for papers by Yuwen Qi